TY  - JOUR
T1  - MDr-tb has new drug foe after fast-track approval
AU  - Voelker R
Y1  - 2013/02/06
N1  - 10.1001/jama.2013.94
JO  - JAMA
SP  - 430
EP  - 430
VL  - 309
IS  - 5
N2  - 
MDR-TB “poses a serious health threat throughout the world, and [bedaquiline] provides much-needed treatment for patients who don't have other therapeutic options,” said Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, in a statement.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2013.94
UR  - http://dx.doi.org/10.1001/jama.2013.94
ER  -